Company intelligence / Profile preview
Delta-Fly Pharma, Inc.
Kawauchi-cho, Tokushima, Japandelta-flypharma.co.jp ↗
- Ownership
- Private
- Employees
- ~13
- Development stage
- Other
01
Overview
The company has multiple programs in clinical development, with DFP-10917 in Phase III clinical trial in the US and Phase I in Japan for relapsed/refractory acute myeloid leukemia, DFP-14323 in Phase III for lung cancer, DFP-17729 in Phase I/II for solid cancer and recently starting Phase 2/3 for pancreatic cancer, DFP-11207 completed Phase I for pancreatic cancer, DFP-14927 in Phase I for hematologic cancer, and DFP-10825 in preclinical trials for gastric/ovarian cancer
- Therapeutic areas
- HematologyOncology
- Modalities
- Small molecules (anticancer drugs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Delta-Fly Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delta-Fly Pharma, Inc..